long intergenic non-protein coding RNA 1762Genealiases: []
Q-omics provides the consensus-scored LINC01762 profile across patient tissues and cancer cell-line models. LINC01762 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, LINC01762 is differentially expressed in 15, with the highest sampling consensus in KIRC. Additionally, LINC01762 RNA expression shows 12,720 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight UVM, KIRC, and TGCT as cancer lineages where LINC01762 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC01762 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC01762 survival associations across molecular data types. LINC01762 RNA expression shows survival associations in the most cancer types (22). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC01762 RNA expression–survival associations across cancer types. High LINC01762 expression shows unfavorable associations in ACC, LIHC and LGG, but favorable associations in UVM, HNSC and KIRP. The UVM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for LINC01762 RNA expression.
This table summarizes LINC01762 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for LINC01762. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC01762 shows lower tumor expression in KIRC, KIRP and KICH and higher tumor expression in STAD, LIHC and COAD. The KIRC box plot shows higher LINC01762 RNA expression in normal versus tumor tissue (log2 FC = −3.045, t-test p < 0.001).
This table shows molecular features associated with LINC01762 in patient tissues and cancer cell lines. In patient samples, LINC01762 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
